Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor.

Abstract

Imatinib is a tyrosine kinase inhibitor with activity in gastrointestinal stromal tumor and a variety of other solid and hematological malignancies. Studies in vitro and in a mouse model suggested that the imatinib might also be active in malignant Leydig cell tumor. We report on the--to our knowledge--first treatment experiment with imatinib in a patient with metastatic Leydig cell tumor. Unfortunately, the tumor progressed during treatment.

• Authors: Michael Froehner, Bettina Beuthien-Baumann, Dag-Daniel Dittert, Ulrich Schuler, Manfred P Wirth
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 58 Issue 5 Pg. 716-8 (Nov 2006) ISSN: 0344-5704 [Print] Germany
• PMID: 16450163 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Benzamides
• Enzyme Inhibitors
• Piperazines
• Pyrimidines
• Imatinib Mesylate
• Protein-Tyrosine Kinases

Topics

• Aged
• Antineoplastic Agents (pharmacology, therapeutic use)
• Benzamides
• Disease Progression
• Enzyme Inhibitors (pharmacology, therapeutic use)
• Humans
• Imatinib Mesylate
• Leydig Cell Tumor (drug therapy, secondary)
• Male
• Piperazines (pharmacology, therapeutic use)
• Protein-Tyrosine Kinases (antagonists & inhibitors)
• Pyrimidines (pharmacology, therapeutic use)
• Testicular Neoplasms (drug therapy, secondary)
• Treatment Failure